Although the Ki67 PI has been widely used as a prognostic and predictive marker in breast cancer, due to the lack of standardized and reproducible counting methods it remains unclear what method, global or hotspot scoring, is the most clinically relevant. This evidence concerns the gene MKI67 and breast cancer.